A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)
- Study Title
- CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma
- Teva Identifier
- FSS-AS-40139
- ClinicalTrials.gov Identifier
- NCT04677959
- Study Status
- Completed
- Trial Condition(s)
- Asthma
- Interventions
- Drug: Fluticasone propionate/salmeterol (FS) | Drug: Albuterol | Drug: Standard of Care Asthma Medication | Drug: Standard of Care Rescue Medication
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 13 Years and older
- Trial Duration
- February 16, 2021 - March 10, 2022
- Phase
- Phase 4